News
The companies will develop AI models trained on real-world data to help identify and diagnose patients with paroxysmal nocturnal hemoglobinuria.
ArteraAI Prostate forecasts potential long-term outcomes of a patient's prostate cancer biopsy slide based on digital pathology images.
The financing comes on top of the company's $900 million annual research and development investment in the U.S.
The company plans to launch the first version of its AI Advocate tool, aimed at helping patients manage and guide their overall healthcare, in the third quarter of this year.
The company's CEO defended its feature as a wellness tool under the 21st Century Cures Act, combating the FDA’s claim that it qualifies as a regulated medical device.
The alliance aims to benefit patients with chronic conditions and allow real-time interoperability among healthcare providers, pharmacies and payers.
The feature will be available via new iOS and watchOS updates, one year after the U.S. International Trade Commission banned Apple from selling its Series 9, Series 10 and Ultra 2 watches.
The company will use the funds to expand its technology offerings and nationwide partnerships.
Data from Dexcom CGMs will be integrated into FriskaAi and will be monitored by AI-powered algorithms that alert patients when action is advised.
Maven Clinic introduces male fertility support tools, Scripta Insights announces a tool to locate cost-effective meds, and XRHealth launches a new platform.